Secondary bladder and rectal cancer risk estimates following standard fractionated and moderately hypofractionated VMAT for prostate carcinoma.
VMAT
hypofractionation
prostate cancer
second cancer risk
Journal
Medical physics
ISSN: 2473-4209
Titre abrégé: Med Phys
Pays: United States
ID NLM: 0425746
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
27
11
2019
revised:
25
03
2020
accepted:
28
03
2020
pubmed:
9
4
2020
medline:
15
5
2021
entrez:
9
4
2020
Statut:
ppublish
Résumé
To estimate the risk for bladder and rectal cancer induction due to standard fractionated (SF) and moderately hypofractionated (HF) volumetric modulated arc therapy (VMAT) for prostate carcinoma. Twelve patients with low or intermediate-risk of prostate cancer referred for external-beam radiotherapy were included in this study. Three computed tomography-based VMAT plans were created for each study participant. The first plan was generated by assuming patient's irradiation with SF-VMAT (78 Gy in 39 fractions). The second and third plans were created on the basis of two different HF schedules (HF-VMAT The average OED of the rectum from SF-VMAT, HF-VMAT The use of VMAT for prostate carcinoma leads to a noteworthy increase of the lifetime risk for bladder and rectal cancer induction compared to that of unexposed people irrespective of the patient's age at the time of treatment and the applied fractionation scheme. The cancer risk data presented in this study may be taken into account by radiation oncologists and medical physicists in the selection of the optimal radiation therapy plan.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2805-2813Informations de copyright
© 2020 American Association of Physicists in Medicine.
Références
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394-424.
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016. Bethesda, MD: National Cancer Institute; 2019.
Dearnaley D, Mossop H, Khoo V, et al. Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-yr outcomes of the randomised, non-inferiority, phase 3 CHHiP trial. Lancet Oncol. 2017;17:1047-1060.
Hamdy FC, Donovan JL, Lane JA, et al. 10-year outcomes after monitoring, surgery, or radiotherapy for localized prostate cancer. N Engl J Med. 2016;375:1415-1424.
National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer, version 4; 2019. www.nccn.org
Morgan SC, Hoffman K, Loblaw DA, et al. Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline. J Clin Oncol. 2018;36:3411-3430.
Teoh M, Clark CH, Wood K, Whitaker S, Nisbet A. Volumetric modulated arc therapy: a review of current literature and clinical use in practice. Br J Radiol. 2011;84:9679-9696.
Hall EJ. Intensity-modulated radiation therapy, protons, and the risk of second cancers. Int J Radiat Oncol Biol Phys. 2006;65:1-7.
Wolff D, Stieler F, Welzel G, et al. Volumetric-modulated arc therapy (VMAT) vs. serial tomotherapy, step-and-shoot IMRT and 3D-conformal RT for treatment of prostate cancer. Radiother Oncol. 2009;93:226-233.
Nguyen BT, Hornby C, Kron T, et al. Optimising the dosimetric quality and efficiency of post-prostatectomy radiotherapy: a planning study comparing the performance of volumetric-modulated arc therapy (VMAT) with an optimised seven-field intensity-modulated radiotherapy (IMRT) technique. J Med Imaging Radiat Oncol. 2012;56:211-219.
Ren W, Sun C, Lu N, et al. Dosimetric comparison of intensity-modulated radiotherapy and volumetric-modulated arc radiotherapy in patients with prostate cancer: a meta-analysis. J Appl Clin Med Phys. 2016;17:254-262.
Huang J, Kestin LL, Ye H, Wallace M, Martinez AA, Vicini FA. Analysis of second malignancies after modern radiotherapy versus prostatectomy for localized prostate cancer. Radiother Oncol. 2011;98:81-86.
Zelefsky MJ, Pei X, Teslova T, et al. Secondary cancers after intensity-modulated radiotherapy, brachytherapy and radical prostatectomy for the treatment of prostate cancer: incidence and cause-specific survival outcomes according to the initial treatment intervention. BJU Int. 2012;110:1696-1701.
Hall EJ, Giaccia AJ. Radiobiology for the radiologist, 7th edn. Philadelphia, PA: Lippincott Wiliams and Wilkins; 2012.
Lee WR, Dignam JJ, Amin MB, et al. Randomized phase III noninferiority study comparing two radiotherapy fractionation schedules in patients with low-risk prostate cancer. J Clin Oncol. 2016;34:2325-2332.
Catton CN, Lukka H, Gu CS, et al. Randomized trial of a hypofractionated radiation regimen for the treatment of localized prostate cancer. J Clin Oncol. 2017;35:1884-1890.
Marks LB, Yorke ED, Jackson A, et al. Use of normal tissue complication probability models in the clinic. Int J Radiat Ocol Biol Phys. 2010;76:S10-S19.
Lawton CAF, Michalski J, El-Naga I, et al. RTOG GU radiation oncology specialists reach consensus on pelvic lymph node volumes for high-risk prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:383-387.
Jorgo K, Polgar C, Major T, et al. Acute and late toxicity after moderate hypofractionation with simultaneous integrated boost (SIB) radiation therapy for prostate cancer. A single institution, prospective study. Pathol Oncol Res. 2019. [Epub ahead of print]. https://doi.org/10.1007/s12253-019-00623-2
Pryor DI, Turner SL, Tai KH, et al. Moderate hypofractionation for prostate cancer: a user’s guide. J Med Imaging Radiat Oncol. 2018;62:232-239.
Aksnessaether BY, Lund JA, Myklebust TA, et al. Second cancers in radically treated Norwegian prostate cancer patients. Acta Oncol. 2019;58:838-844.
Wallis CJD, Mahar AL, Choo R, et al. Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis. BMJ. 2016;352:i851.
Mazonakis M, Damilakis J. Cancer risk after radiotherapy for benign diseases. Phys Med. 2017;42:285-291.
Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model. 2011;8:27.
Geng C, Moteabbed M, Xie Y, Schuemann J, Yock T, Paganetti H. Assessing the radiation-induced second cancer risk in proton therapy for pediatric brain tumors: the impact of employing a patient-specific aperture in pencil beam scanning. Phys Med Biol. 2016;61:12-22.
Mazonakis M, Lyraraki E, Damilakis J. Second cancer risk assessments after involved-site radiotherapy for mediastinal Hodgkin lymphoma. Med Phys. 2017;44:3866-3874.
Mazonakis M, Stratakis J, Lyraraki E, Damilakis J. Risk of contralateral breast and ipsilateral lung cancer induction from forward-planned IMRT for breast carcinoma. Phys Med. 2019;60:44-49.
Mazonakis M, Tzedakis A, Lyraraki E, Damilakis J. Radiation dose and cancer risk to out-of-field and partially in-field organs from radiotherapy for symptomatic vertebral hemangiomas. Med Phys. 2016;43:1841-1848.
Murray LJ, Thompson CM, Lilley J, et al. Radiation-induced second primary cancer risks from modern external beam radiotherapy for early prostate cancer: impact of stereotactic ablative radiotherapy (SABR), volumetric modulated arc therapy (VMAT) and flattening filter free (FFF) radiotherapy. Phys Med Biol. 2015;60:1237-1257.
BEIR. Health Risks from Exposure to Low Levels of Ionizing Radiation: BEIR VII- Phase 2. Washington, DC: National Academy of. Science; 2006.
Arias E, Xu J. United States life tables, 2017. Natl Vital Stat Rep. 2019;68:1-66.
Alvarez-Moret J, Koelbl O, Bogner L. Quasi-IMAT technique and secondary cancer risk in prostate cancer. Strahlenther Onkol. 2009;185:248-253.
Schneider U, Lomax A, Besserer J, Pemler P, Lombriser N, Kaser-Hotz B. The impact of dose escalation on secondary cancer risk after radiotherapy of prostate cancer. Int J Radiat Oncol Biol Phys. 2007;68:892-897.
Stathakis S, Li J, Ma CCM. Monte Carlo determination of radiation-induced cancer risks for prostate patients undergoing intensity-modulated radiation therapy. J Appl Clin Med Phys. 2007;8:14-27.
Harrison RM. Second cancers following radiotherapy: a suggested common dosimetry framework for therapeutic and concomitant exposures. Br J Radiol. 2004;77:986-990.
Xu XG, Bednarz B, Paganetti H. A review of dosimetry studies on external-beam radiation treatment with respect to second cancer induction. Phys Med Biol. 2008;53:R193-R241.
Rechner LA, Howell RM, Zhang R, Etzel C, Lee AK, Newhauser WD. Risk of radiogenic second cancers following volumetric modulated arc therapy and proton arc therapy for prostate cancer. Phys Med Biol. 2012;57:7117-7132.
Stokkevag CH, Engeseth GM, Hysing LB, Ytre-Hauge KS, Ekanger C, Muren LP. Risk of radiation-induced secondary rectal and bladder cancer following radiotherapy of prostate cancer. Acta Oncol. 2015;54:1317-1325.
Mavroidis P, Komisopoulos G, Buckey C, et al. Radiobiological evaluation of prostate cancer IMRT and conformal-RT plans using different treatment protocols. Phys Med. 2017;40:33-41.
Fontenot JD, Lee AK, Newhauser WD. Risk of secondary malignant neoplasms from proton therapy and intensity modulated X-ray therapy for early-stage prostate cancer. Int J Radiat Oncol Biol Phys. 2009;74:616-622.
Kleiner H, Podgorsak MB. The dosimetric significance of using 10 MV photons for volumetric modulated arc therapy for post-prostatectomy irradiation of the prostate bed. Radiol Oncol. 2016;50:232-237.
Pasler M, Georg D, Wirtz H, Lutterbach J. Effect of photon-beam energy on VMAT and IMRT treatment plan quality and dosimetric accuracy for advanced prostate cancer. Strahlenther Onkol. 2011;187:792-798.
Schneider U, Sumila M, Robotka J, Gruber G, Mack A, Besserer J. Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol. 2011;6:67.